Greater Certainty in Drug Development

これから発売となる新しいソフトウェアPhoenix Cloud の画期的な Tables, Figures, and Listings（TFL）モジュールをいち早く体験してみませんか。This innovative tool promises to transform the way you handle TFL creation and management, delivering swift results, unparalleled flexibility, and seamless teamwork.&nbsp;&nbsp; In this exclusive webinar, you&#8217;ll delve into key highlights, including:&nbsp; For whom the webinar will be &hellip; <a href="https://jp.certara.com/webinar/exclusive-preview-discovering-the-new-tfl-module-in-phoenix-cloud-apac-webinar/">Continued</a>

Join us for an exclusive webinar led by Simcyp’s world-class experts to explore the newest developments in the Simcyp Simulator, the gold standard in physiologically based pharmacokinetic (PBPK) modeling. With the release of Version 24, the Simcyp Simulator introduces cutting-edge enhancements that further elevate its capabilities. The latest features in Version 24 include: Don’t miss &hellip; <a href="https://jp.certara.com/webinar/exploring-the-innovations-in-simcyp-simulator-version-24/">Continued</a>

The biopharmaceutical industry is experiencing a critical stage of innovation as teams invest in in silico approaches to virtualize trials and accelerate time to market. For Certara, this innovation is converging between generative AI and quantitative systems pharmacology (QSP). As demand for QSP grows, it presents a unique opportunity for pharmaceutical companies to rethink their &hellip; <a href="https://jp.certara.com/webinar/industrializing-qsp-using-generative-ai-to-accelerate-the-model-life-cycle/">Continued</a>

For the past couple of decades, leading American institutions, pharmaceutical and biotechnology companies, as well as the US FDA have been using quantitative tools (model-informed drug development; MIDD) to further their understanding of drug development assets. This integrated armamentarium has fueled industry consortiums, public-private partnerships, as well as several regulatory guidance documents. In this blog, … Continued

Efficient drug development relies on informed decision-making. For toxicologists, having timely access to nonclinical study data while studies are in progress is a game-changer. Imagine the ability to monitor research findings as they develop. This change would allow you to adjust study designs in the moment and provide actionable insights to your team.   However, traditional … Continued

Streamline developing a summary of changes for an Investigator’s Brochure, a document that summarizes the clinical and nonclinical data on an investigational drug.